

RAD'S INTEGRINS TECHNOLOGY FEATURED IN CANCERS JOURNAL

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, **is pleased to announce its best in class $\alpha\beta6$ Integrin platform technology has been featured in prestigious research journal *Cancers*.**

Radiopharm's $\alpha\beta6$ platform was invented by highly regarded Integrin expert Professor Johannes Notni, with evidence that the **$\alpha\beta6$ Integrin is found in** a variety of challenging cancers including **pancreatic, head and neck, and certain lung cancers**. It may provide outstanding performance in radiolabelling (tracking the movement / breakdown of target molecules) with the Ga-68 radiopharmaceutical tracer, showing promise in the early detection of these cancers using PET imaging.

The manuscript published in *Cancers*, titled 'It's Time to Shift the Paradigm: Translation and Clinical Application of Non- $\alpha\beta3$ Integrin Targeting Radiopharmaceuticals', investigated recent research on other radiolabelled integrin ligands and the potential clinical benefit that may result from their development.

The conclusion to the manuscript indicated that of all integrins, $\alpha\beta6$ is 'arguably the most promising target structure for radiotheranostics', noting its broad clinical scope across oncology as well as fibrotic diseases, which may include COVID-19 related syndromes.

While over the past two decades key studies have focused strongly on the subtype $\alpha\beta3$, the largest number of recent non- $\alpha\beta3$ integrin targeted first-in-human applications has been reported for radiolabelled compounds homing to $\alpha\beta6$. The manuscript notes this might lead to a paradigm change and trigger the placement of $\alpha\beta3$ by $\alpha\beta6$ 'as the most popular integrin in theranostics'.

"To be published in *Cancers* is an excellent recognition of Professor Notni and his potentially transformational work," said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics.

"A Phase 1 compassionate use diagnostic approach is ongoing in Germany, targeted at pancreatic and head and neck cancer and up to now including 15 patients. Under our Sponsored Research Agreement with Professor Notni and his company, TRIMT GmbH, we look forward to developing the technology toward a therapeutic application in due course."

The full publication can be viewed at: <https://www.mdpi.com/2072-6694/13/23/5958/htm>

RAD to present at Targeted Radiopharmaceuticals Summit & MedInvest Oncology Investor Conference

Radiopharm is also pleased to announce Mr Canevari will present at the 3rd Annual Targeted Radiopharmaceuticals Summit (TRP), being held in Berlin 7-9 December 2021.

He will present on "The Blue Ocean of Radiopharmaceuticals" at 5:30pm CET Wednesday 8 December (3:30am AEDT Thursday 9 December), discussing the strong growth opportunities of therapeutic radiopharmaceuticals in becoming a key pillar in oncology, and how Radiopharm's pipeline is uniquely positioned to deliver potentially transformative patient outcomes.

TRP hosts the leading industry and academic researchers looking to develop the next generation of therapeutic and diagnostic radioligands. The event allows delegates to actively participate in a bench to bedside discussion on the radiopharmaceutical product development process. It covers the latest antibody and peptide-based targeting technologies expected to further the rapidly growing radiopharmaceutical field.

The 2021 iteration of the event can be attended virtually, with further details available at: <https://targeted-radiopharma.com/>

This week Mr Canevari will also be presenting as part of the MedInvest Oncology Investor Conference, being held virtually 7-10 December 2021.

He will discuss the Radiopharm Theranostics portfolio and investment proposition during a session beginning 10am Thursday 9 December US EST (1am Friday 10 December AEDT).

The semi-annual meeting will feature three days of live streaming including company presentations, keynote speakers and additional one-on-one meeting opportunities. It is attended by investors seeking opportunities in private and public cancer companies.

For more details/registration please visit: <https://www.medinvestconferences.com/>

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>